Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HCP1803 Dose-response in Essential Hypertension
NCT03897868Phase 2Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Mar 2019
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of HCP-1803 in essential hypertension (7 arms), sponsored by Hanmi Pharmaceutical. Primary endpoint: Change from baseline in sitting systolic blood pressure at 8 weeks. Started Mar 2019; status: completed.
02
Drugs
HCP-1803
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT03897868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03897868.